1-3 of 3
Ye Hua, MD
Close
Sort by
Journal Articles

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Jun Zhu, MD PhD, Junning Cao, MD, Lugui Qiu, MD PhD, Junyuan Qi, MD, Yuqin Song, MD PhD, Meifeng Tu, MD PhD, Dongmei Ji, MD PhD, Weina Shen, MD, Mingyuan Sun, MD, Ye Hua, MD, Chen Yang, MD, Chen Yu, MD, Jian Wang, PhD, Guangxiu Dai, PhD, Weiguo Su, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5324.
https://doi.org/10.1182/blood-2018-99-111648
Published: 2018
Journal Articles

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Craig C. Hofmeister, MD, David Siegel, MD, PhD, Sagar Lonial, MD, Jacob P. Laubach, MD, Yvonne A. Efebera, MD, David H. Vesole, MD, PhD, Ajay K. Nooka, MD, MPH, Jacalyn Rosenblatt, MD, MSc, Noopur Raje, MD., Mohamed H. Zaki, MD, PhD, Ye Hua, MD, MPH, Yan Li, PhD, Sheetal Shah, BA, Jianming Wang, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2013) 122 (21): 1969.
https://doi.org/10.1182/blood.V122.21.1969.1969
Published: 2013
Journal Articles

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Craig C. Hofmeister, MD, David Siegel, MD, PhD, Sagar Lonial, MD, Mohamad Zaki, MD, PhD, Ye Hua, MD, MPH, Sheetal Shah, BA, Jianming Wang, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2012) 120 (21): 727.
https://doi.org/10.1182/blood.V120.21.727.727
Published: 2012